Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DG9LF8
|
|||
| Drug Name |
DKY709
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Novartis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Zinc finger protein Helios (IKZF2) | Target Info | Degrader | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03891953) Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health. | |||
| REF 2 | Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov. 2021 Apr;20(4):247-250. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.